STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £66.31m
- £80.07m
- $49.70m
Brief: Shield Therapeutics Reports Q1 2026 Group Net Revenues Of $18 Million
Shield Therapeutics - Q1 2026 Trading Update
Brief: Shield Therapeutics Reports 2025 Group Net Revenues & Other Income At $49.7 Million
Shield Therapeutics - Audited results for year ended 31 December 2025
RCS - Shield Therapeutics - Publication of Report, Reinforcing FDA Approval
Brief: Shield Therapeutics Says Fda Approves Accrufer Oral Iron For Children 10 And Older
Brief: Shield Therapeutics Says FDA Grants Additional Exclusivity For ACCRUFeR
Brief: Shield Therapeutics Announces Approval For ACCRUFeR In China Expected In Q1 2026
Brief: Shield Therapeutics Expects to Deliver Operating Profit In 2026
Shield Therapeutics - Q4 2025 Trading Update
Brief: Shield Therapeutics Announces FDA Approval Of Extension For ACCRUFeR
Shield Therapeutics - FDA approves extension for ACCRUFeR®
Shield Therapeutics - Block Listing Application
RCS - Shield Therapeutics - Shield Wins Gold at Titan Branding Awards
Brief: Shield Therapeutics Says Loan Facility Extended To Up To $50 Million
Shield Therapeutics - Amends Senior Secured Debt Financing
Brief: Shield Therapeutics Says Accrufer Receives Marketing Authorisation In South Korea
Shield Therapeutics - ACCRUFeR receives Authorisation by Korean Ministry
Shield Therapeutics - Q3 2025 Trading Update